352 related articles for article (PubMed ID: 36961665)
1. A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson's disease: beneficial or detrimental effects.
Alrouji M; Al-Kuraishy HM; Al-Gareeb AI; Saad HM; Batiha GE
Inflammopharmacology; 2023 Apr; 31(2):673-688. PubMed ID: 36961665
[TBL] [Abstract][Full Text] [Related]
2. Non-steroidal anti-inflammatory drugs in Parkinson's disease.
Esposito E; Di Matteo V; Benigno A; Pierucci M; Crescimanno G; Di Giovanni G
Exp Neurol; 2007 Jun; 205(2):295-312. PubMed ID: 17433296
[TBL] [Abstract][Full Text] [Related]
3. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies.
Rees K; Stowe R; Patel S; Ives N; Breen K; Clarke CE; Ben-Shlomo Y
Cochrane Database Syst Rev; 2011 Nov; (11):CD008454. PubMed ID: 22071848
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases.
Asanuma M; Miyazaki I; Ogawa N
Curr Pharm Des; 2004; 10(6):695-700. PubMed ID: 14965332
[TBL] [Abstract][Full Text] [Related]
5. Role of Brain Liver X Receptor in Parkinson's Disease: Hidden Treasure and Emerging Opportunities.
Alnaaim SA; Al-Kuraishy HM; Alexiou A; Papadakis M; Saad HM; Batiha GE
Mol Neurobiol; 2024 Jan; 61(1):341-357. PubMed ID: 37606719
[TBL] [Abstract][Full Text] [Related]
6. Anti-Inflammatory and Neuroprotective Mechanisms of GTS-21, an α7 Nicotinic Acetylcholine Receptor Agonist, in Neuroinflammation and Parkinson's Disease Mouse Models.
Park JE; Leem YH; Park JS; Kim DY; Kang JL; Kim HS
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457238
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
[TBL] [Abstract][Full Text] [Related]
8. Orexin pathway in Parkinson's disease: a review.
Alrouji M; Al-Kuraishy HM; Al-Gareeb AI; Zaafar D; Batiha GE
Mol Biol Rep; 2023 Jul; 50(7):6107-6120. PubMed ID: 37155018
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective and Anti-Inflammatory Effects of Pioglitazone on Parkinson's Disease: A Comprehensive Narrative Review of Clinical and Experimental Findings.
Zamanian MY; Terefe EM; Taheri N; Kujawska M; Tork YJ; Abdelbasset WK; Shoukat S; Opulencia MJC; Heidari M; Alesaeidi S
CNS Neurol Disord Drug Targets; 2023; 22(10):1453-1461. PubMed ID: 36200161
[TBL] [Abstract][Full Text] [Related]
10. Novel anti-inflammatory and neuroprotective agents for Parkinson's disease.
Lu L; Li F; Wang X
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):232-40. PubMed ID: 20015029
[TBL] [Abstract][Full Text] [Related]
11. The conceivable role of prolactin hormone in Parkinson disease: The same goal but with different ways.
Al-Kuraishy HM; Jabir MS; Al-Gareeb AI; Albuhadily AK
Ageing Res Rev; 2023 Nov; 91():102075. PubMed ID: 37714384
[TBL] [Abstract][Full Text] [Related]
12. The effects of cholesterol and statins on Parkinson's neuropathology: a narrative review.
Al-Kuraishy HM; Fahad EH; Al-Windy S; El-Sherbeni SA; Negm WA; Batiha GE
Inflammopharmacology; 2024 Apr; 32(2):917-925. PubMed ID: 38499742
[TBL] [Abstract][Full Text] [Related]
13. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease.
Klegeris A; McGeer PL
Curr Alzheimer Res; 2005 Jul; 2(3):355-65. PubMed ID: 15974901
[TBL] [Abstract][Full Text] [Related]
14. Non-steroidal anti-inflammatory drugs and risk of Parkinson's disease in the elderly population: a meta-analysis.
Poly TN; Islam MMR; Yang HC; Li YJ
Eur J Clin Pharmacol; 2019 Jan; 75(1):99-108. PubMed ID: 30280208
[TBL] [Abstract][Full Text] [Related]
15. Galangin Reduces the Loss of Dopaminergic Neurons in an LPS-Evoked Model of Parkinson's Disease in Rats.
Chen G; Liu J; Jiang L; Ran X; He D; Li Y; Huang B; Wang W; Fu S
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29267220
[TBL] [Abstract][Full Text] [Related]
16. Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease.
Asanuma M; Miyazaki I
Curr Pharm Des; 2008; 14(14):1428-34. PubMed ID: 18537665
[TBL] [Abstract][Full Text] [Related]
17. Hordenine inhibits neuroinflammation and exerts neuroprotective effects via inhibiting NF-κB and MAPK signaling pathways in vivo and in vitro.
Su Y; Liu Y; He D; Hu G; Wang H; Ye B; He Y; Gao X; Liu D
Int Immunopharmacol; 2022 Jul; 108():108694. PubMed ID: 35349959
[TBL] [Abstract][Full Text] [Related]
18. The Mechanistic Role of Thymoquinone in Parkinson's Disease: Focus on Neuroprotection in Pre-Clinical Studies.
Uddin MN; Hoq MI; Jahan I; Siddiqui SA; Clinton CD; Ibrahim M; Islam MS; Jakaria M
Curr Mol Pharmacol; 2021; 14(6):1083-1092. PubMed ID: 33402092
[TBL] [Abstract][Full Text] [Related]
19. Neuroinflammation in Parkinson's Disease and its Treatment Opportunities.
Çınar E; Tel BC; Şahin G
Balkan Med J; 2022 Sep; 39(5):318-333. PubMed ID: 36036436
[TBL] [Abstract][Full Text] [Related]
20. Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications.
Wilms H; Zecca L; Rosenstiel P; Sievers J; Deuschl G; Lucius R
Curr Pharm Des; 2007; 13(18):1925-8. PubMed ID: 17584117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
